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Abstract
Chronic diseases are the leading causes of morbidity and mortality in Europe, accounting for more than 2/3 of all
death causes and 75 % of the healthcare costs. Heart failure is one of the most prominent, prevalent and complex
chronic conditions and is accompanied with multiple other chronic diseases. The current approach to care has
important shortcomings with respect to diagnosis, treatment and care processes. A critical aspect of this situation is
that interaction between stakeholders is limited and chronic diseases are usually addressed in isolation.
Health care in Western countries requires an innovative approach to address chronic diseases to provide
sustainability of care and to limit the excessive costs that may threaten the current systems. The increasing
prevalence of chronic diseases combined with their enormous economic impact and the increasing shortage of
healthcare providers are among the most critical threats. Attempts to solve these problems have failed, and future
limitations in financial resources will result in much lower quality of care. Thus, changing the approach to care for
chronic diseases is of utmost social importance.
Keywords: Predictive preventive personalised medicine, Cardiovascular disease, Heart failure, Chronic diseases, Care
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Background
Chronic diseases are by far the leading causes of mortal-
ity and morbidity in Europe [1]. Together, heart disease,
stroke, cancer, chronic respiratory diseases, diabetes mel-
litus and other chronic diseases represent 2/3 of all
death causes. The prevalence of chronic diseases is rising
due to changes in lifestyle, increasing healthcare stan-
dards and therefore lifespan and is most relevant to the
ageing population. Besides adverse effects on quality of
life, chronic diseases pose a serious economic burden as
75 % of all healthcare costs are comprised of chronic
diseases [2].
A significant contribution to the burden is the co-
concurrence of multiple chronic diseases (co-morbid-
ities), which are increasingly frequent [3] and are present
in 1/3 of the adult population. Chronic diseases should
not be treated separately [4], but caregivers often are not
capable to consider the interaction of multiple factors
relevant for individual care plans. Also, clinical evidence
merely focuses on single diseases and fails to provide
evidence on how to manage multiple diseases as patients
with co-morbidities are usually excluded from large clin-
ical trials. Multiple diseases often require involving sev-
eral caregivers. However, hospital care, ambulatory
specialist care and primary care are subdivided into nu-
merous entities, based mainly on medical specialty [5].
The existing gaps in coordination and communication
between the caregivers hamper the care process [6] and
are associated with medical errors [7]. Hence, providing
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challenge.
Heart failure—a prominent example of chronic diseases
Heart failure is a chronic, debilitating disease and repre-
sents a frequent co-morbidity in patients with other pri-
mary diseases. Heart failure care is often further
complicated by general frailty and a need for highly
organised and integrated care. Considering its complex-
ity, heart failure care involving multiple specialists is an
ideal, representative model to change the strategy of care
for multiple chronic diseases.
The incidence (390 per 100,000 person years [8]) of
heart failure is alarmingly high, and its prevalence is
steadily rising. Approximately 2 % of the population in
Western societies suffers from heart failure, and this fig-
ure will rise to 3 % by 2025 (i.e. >20 million people in
Europe) [9]. The percentage rises sharply with age to ap-
proximately 10 % of the population aged 75 years or
older or even almost 20 % in those aged 85 years or
more [1]. This high overall prevalence is partly caused
by the increase in unhealthy lifestyle, such as poor diet
and lack of physical activity of the general population.
Paradoxically, a further increase of heart failure preva-
lence is unavoidable, not only due to the ageing of the
population but also due to decreased mortality by better
treatment of underlying diseases such as myocardial in-
farction. Treatment reduces acute mortality, but leaves
patients with damaged hearts resulting in heart failure
[10], specifically if the unhealthy lifestyle is not cor-
rected. In addition, associated diseases, such as hyper-
tension and atrial fibrillation, are expected to increase in
the future [11]. Finally, treatment of heart failure im-
proves lifespan, but lacks to effectively cure it, further
contributing to the increase in prevalence, which may
represent a rising economic burden.
Despite improved treatment, heart failure is still asso-
ciated with debilitating symptoms, high hospitalisation
rates and poor prognosis [12]. This compares unfavour-
ably with other chronic diseases with an average 5-year
survival rate after first heart failure admission of only
35–50 % [13, 14]. In-hospital care is frequent, often
lengthy and costly (61 % of costs consist of in-hospital
care [15]), accounting for approximately 2 % of total ex-
penditure on health care in Western countries [9].
Within only 3 months after discharge from hospital,
24 % of patients are readmitted [10], highlighting the
challenges in heart failure care. Reducing hospitalisation
is highly warranted to reduce costs particularly in pa-
tients with multiple co-morbidities as (re-)hospitalisation
is often caused by other morbidities. Research on health-
care processes in heart failure in three countries (the
Netherlands, Belgium, Germany) shows that care is not
optimally organised and presents significant overlap,insufficient communication and poorly defined path-
ways/strategies in care [16]. Thus, there is a significant
room for streamlining care to further reduce costs.
Heart failure and co-morbidities: complicate diagnosis,
treatments and follow-up
Risk factors for heart failure are overlapping with other
chronic diseases, and therefore, patients with heart fail-
ure frequently have many co-morbidities. More than
40 % of heart failure patients have five or more co-
morbidities (e.g. atrial fibrillation, hypertension, diabetes,
COPD, renal failure, rheumatic disorders, stroke, depres-
sion, cancers), while almost none is free of any co-
morbid condition [17, 18]. The frequent presence of co-
morbidities complicates diagnosis, treatment and follow-
up and is an important reason for inadequately orga-
nised care. The cumulative number of drugs for these
patients increases the risk of interactions and adverse ef-
fects. Co-morbidities may interfere with treatment ef-
fects of heart failure medication [19], and most of them
are associated with worse prognosis [20]. Hence, co-
morbidities significantly complicate care and patients
with multiple diseases should be treated holistically and
in a personalised way, but in reality, this is not the case.
Current practice hardly addresses an integrated manage-
ment of co-morbidities. Interaction and communication
between patients, relatives and caregivers as well as
alignment between caregivers in different settings are
often poor, which may be one of the most important
reasons for insufficient care [16].
Care process to be redesigned
Aspects such as diagnosis, treatment, follow-up and or-
ganisation all play important roles in the care process to
optimise outcome with similar difficulties observed
across different countries in Europe.
Diagnosis
Inaccurate or late diagnosis of heart failure, underlying
reason(s) and complications as well as co-morbidities re-
sult in poor quality of life and outcome due to poor pre-
diction of personalised needs, resulting in inadequate
treatment and lack of preventing progression. Hence,
there is a need for guidance in determining which diag-
nostic tests should be performed and in adequately
interpreting results.
Symptoms of heart failure, like dyspnoea, are often
non-specific and do not discriminate heart failure from
other diseases. Especially in primary care where patients
present at early stages and symptoms are mild, heart fail-
ure is difficult to diagnose [21]. Approximately 50 % of
heart failure cases are diagnosed by the general practi-
tioners (GPs) [22]. Most other patients are diagnosed at
the time of the first hospitalisation. As diagnosis is
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nosed. Evaluation of the diagnostic process shows that in
both primary and secondary care, basic investigations
mentioned in the guidelines are often not performed
[10, 23]. All these shortcomings can lead to hospitalisa-
tion or even death [10]. Importantly, a substantial num-
ber of these hospitalisations as well as progression of
disease(s) could be prevented by early and accurate iden-
tification and/or patient monitoring.
Treatment
Treatment plans for heart failure patients are not adequately
personalised and do not consider co-morbidities. This may
cause under- or overtreatment, resulting in side effects and
poor outcome. There is an urgent need for personalised treat-
ment plans taking all patient’s characteristics into account.
Effective therapies for heart failure are often not uti-
lised in a safe, timely, equitable, patient-centred and effi-
cient manner [24]. This is partly caused by insufficient
awareness of relevant research evidence due to the rap-
idly changing therapeutic field. Significant variation is
observed in prescribing heart failure medication in dif-
ferent care settings. Although guidelines recommend
treatment plans for specific conditions, they lack to give
advice on comprehensive treatment plans for multiple
chronic diseases. Still, considering the increasing num-
ber of medications used, those personalised plans are
crucial as overall, more than half of the patients use four
or more different medications [25]. Besides the lack of
personalised treatment planning, patient adherence and
persistence of prescribed treatment is poor. Patients are
confused by the high number of medications and the
transition of care setting (in-hospital medication is ad-
ministered while at home the patient is responsible).
The increasing complexity, assisted by developments in
the information and communication technology (ICT) sec-
tor, resulted in decision-support systems for heart failure
care. The main goal of such systems is to improve the clin-
ical decision making process by providing the necessary
knowledge to procure patients with optimal care. Algo-
rithms generate recommendations to support healthcare
professionals. Still, their usage is hampered by different
challenges for successful implementation. (1) Integration
into clinical setting is difficult since care pathways and
“ownership” are hardly defined; (2) comprehensibility in
terms of ease of use and language is often not given; (3)
systems are mostly used as add-ons to existing care instead
of substitution of care; (4) semantic and technical inter-
operability of existing systems as well as with electronic pa-
tient records is a major challenge that is not yet resolved;
(5) involvement of patients (or their family) regarding self-
management is basically absent. Importantly, these systems
are usually limited to one specific disease, failing to address
co-morbidities and personalised needs of patients. Notsurprisingly, there is no evidence yet that such systems
would improve outcome and there is currently no imple-
mentation of decision support for personalised treatment.
Capabilities and effectiveness of various remote monitoring
systems have been reviewed recently, showing these limita-
tions [26].
Chronic management
Lack of follow-up strategies and patient involvement re-
sults in poor outcomes despite increasing costs. Hence,
there is a need to develop and implement personalised
patient support strategies.
Once a patient is diagnosed and treatment started,
follow-up strategies involving patients should be devel-
oped. Patients have important responsibilities including
adherence to treatment, making significant lifestyle
changes, monitoring themselves and reacting in case of
problems. The importance of this is often recognized,
but seldom implemented [27], and interventions are
often not integrated as a whole, but focussed on separate
parts of treatment. Self-management is an active cogni-
tive process undertaken by patients to manage their own
chronic diseases [28]. It encompasses the adoption of
numerous practices, follow-up with caregivers and emo-
tional management [24]. However, adoption of each of
these individual care components may be difficult for
patients as they may be hard to understand, seen as
inacceptable intrusion in daily life and may interfere
with recommendations given related to co-morbidities.
Different programmes have been set up to support pa-
tients such as structured telephone support, self-
management support programmes and tele-monitoring, but
implementation is limited [29]. These programmes usually
are not sufficiently personalised, particularly not addressing
specific co-morbidities. There is evidence of efficacy of self-
management programmes [30], but evidence is of mixed
quality and does not adequately take account programme
complexity and heterogeneity [31]. Moreover, results in clin-
ical practice may be substantially different as found in
Canada [32]. Possibly, disease managed programmes or ap-
proaches may work in some groups of patients, but there
may be also a large group of patients that is not responding
optimally or not at all. Tele-monitoring and structured tele-
phone support of patients with heart failure may reduce
hospitalisation and mortality rates [33]. However, two recent
large randomised controlled trials failed to improve outcome
[34, 35]. Invasive monitoring may be more efficient, but
again focussed on heart failure only and due to the invasive
nature applicable to a limited part of patients only [36]. In
clinical practice, programmes failed to show consistent
improvements and it is unclear which parts are clinically
important [37]. Usually, recorded parameters are limited
and give little insights in the actual condition of individual
patients [26]. Thus, there are limitations regarding
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long-term follow-up, particularly regarding self-
management. Moreover, decision support still is in its infan-
cies. In part, this may be related to the fact that short-term
outcome measure and surrogate parameters are not suffi-
ciently solid to support personalised decision making.
Interactions
Lacking interactions between stakeholders leads to poor
comprehensibility of the care process. There is a need toFig. 1 Most important stakeholders in the care of a HF patient. Involvemen
Blue patient and family, green primary care, brown secondary/tertiary carefacilitate communication including patients to personal-
ise management.
All stakeholders of an individual patient should collab-
orate and interact appropriately. In the care for patients
with chronic diseases, many stakeholders are involved
(Fig. 1). However, communication and interaction be-
tween patients, their relatives and caregivers as well as
among caregivers have received little attention so far, are
poorly defined and are largely insufficient. We found
that this is one of the most important reasons why caret of specialists other than cardiologist as required (not a complete list).
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efficiency and costs [16].
Communication between patients and caregivers is
often poor and not oriented at the individual patient
[38]. Patients see up to 15–23 caregivers within both pri-
mary and secondary care annually [39]. Patients are
poorly informed and do not understand their condition.
Some may not even know that they have been diagnosed
with heart failure. They often are not aware of the roles
and responsibilities of the different caregivers. The lack
of communication between patients and their caregivers
results not only in lower quality of care but also quality
of life, associated with poor adherence to treatment and
required changes in lifestyle. Obviously, this forms a
major hurdle towards personalised management of pa-
tients with chronic diseases.
Unfortunately, interaction between different caregivers
involved in the care for different co-morbidities is often
absent. Sometimes specialists are unaware of the pres-
ence of co-morbidities and the co-medication a patient
is taking [6]. Moreover, information provided by special-
ists to GPs is often late and poorly understood by the
GP. A multidisciplinary approach and a central coordin-
ator are often lacking. In clinical reality, even the simple
communication loop between two caregivers (e.g. GP
and cardiologist, Fig. 2) is usually incomplete, which be-
comes more evident the more caregivers are involved.
To improve these shortcomings, there has been a shift
in heart failure management towards a multidisciplinary
approach in recent years. This shift has led to several
randomised controlled trials of multidisciplinary, orga-
nised and/or managed care [40]. Most of these ap-
proaches applied to specialist personnel mainly within
multidisciplinary teams. In some of these programmes,
formal links were established between healthcareFig. 2 Required information exchange between two caregiversprofessionals including not only cardiology care, which
resulted in fewer hospital readmissions than routine care
patients in some studies [39, 41]. However, in a real-
world setting, multidisciplinary care in Canada was
found to slightly reduce mortality, but at the cost of
even a significant increase in heart failure-related admis-
sions [32].
Attempts to implement multidisciplinary heart failure
care have only been partly successful in a few European
countries. An important reason for the poor implementa-
tion might be that most programmes are stand-alone, fo-
cusing on limited aspects of heart failure care. Lack of
standardisation, limited evidence of cost-effectiveness as
well as lack of flexibility and acceptance by healthcare pro-
viders are additional reasons for poor implementation.
Evidence-based care
Clinical evidence retains patients with co-morbidities
from optimal care. There is a need for evidence-based
personalised care to address co-morbidities of individual
patients.
To facilitate care for heart failure patients, the Euro-
pean Society for Cardiology (ESC) and other authorities
developed evidence-based guidelines [12]. These guide-
lines are complex and adherence to them is regrettably
poor [42]. They cover recommendations for heart fail-
ure, but they are still very limited with respect to care
for co-morbidities.
Multiple treatment trials have been performed resulting
in evidence-based clinical guidelines. These trials applied
precisely defined inclusion and exclusion criteria usually
not including patients with co-morbidities. Thus, the ma-
jority of patients are not properly represented in the large
treatment trials [43]. Hence, evidence is limited for pa-
tients seen in daily practice, i.e. with multiple chronic dis-
eases. Various systematic reviews of guidelines concluded
that evidence in older patients with co-morbidities is poor
[43–45] and that adherence to current guidelines in that
specific subset of patients may even have undesirable ef-
fects [46]. Various case-control studies found an increased
risk of severe adverse drug reactions in patients at older
age and particularly with multiple co-morbidities [47–49],
but there is a lack of clinical recommendations integrating
different guidelines to support personalised care for pa-
tients with multiple chronic diseases.
Table 1 shows three potential and realistic patient sce-
narios. Scenario 1 is fully covered by the guidelines, but
represents only approximately 10 % of the heart failure
population. Scenario 2 gives an example of a patient with
one important co-morbidity, which is largely covered by
the guidelines, but leaves patients with limited treatment
options for the co-morbidity. Again, this is not yet the typ-
ical heart failure patient. Scenario 3 is more frequently oc-
curring regarding complexity of multiple chronic diseases.
Table 1 Examples of different patient scenarios with similar underlying cardiac disease, depicting how the presence of
co-morbidities significantly impacts treatment considerations and where guidelines fail to give guidance
Heart failure patient scenario Presence of co-
morbidities
Treatment considerations
Stage C heart failure [12] (male, 74 y, LVEF 25 %)
due to coronary artery disease (CAD) with
dyspnoea during exercise only, clinically stable
Scenario 1
- No major co-morbidities
(mild COPD, diabetes on
diet only)
• Guidelines recommended medical heart failure therapy: ACE inhibitor,
β-blocker, eplerenone, ev. loop diuretic; ICD placement
• Guidelines recommended CAD therapy: statin, low-dose aspirin
• Diabetes diet
• No fluid and salt excess
• Physical exercise
Scenario 2
- Arthritis as single
important co-morbidity
Additional treatments required:
• Anti-inflammatory drug (NSAID) might interact with ACE-inhibitor
resulting in acute renal failure
• Chronic NSAID use might disturb fluid balance and worsen heart failure
• Patient might avoid exercise due to pain. He may benefit not only from
involvement of physiotherapy but also from clear communication between
cardiologist and rheumatologist to discuss individually tailored therapy and
exercise plan
Scenario 3
- Paroxysmal symptomatic
atrial fibrillation
- More severe diabetes
- Reduced renal function
(creatinine 220 μmol/l)
- Iron deficiency anaemia
Additional treatments required:
• Higher dose of loop diuretic, but may further worsen
renal function
• Amiodarone for rhythm control (might cause pulmonary fibrosis
and hyper- or hypothyroidism)
• Oral anticoagulation; may cause interaction with other medication!
• 1 or 2 antidiabetic drugs; may cause interaction with other medication!
• Iron deficiency requires search for bleeding (often gastrointestinal)
and ev H2-blocker; may cause interaction with other medication!
• Iron infusion and possibly erythropoietin due to renal failure
Additional important aspects (incomplete list):
• Patient was told by GP to drink sufficiently to improve renal
function; might result in worsening heart failure. Proper instruction
of patient and collaboration between GP, nephrologist, cardiologist
and patient needed!
• Renal failure: ACE-inhibitors and eplerenone might induce hyperkalaemia
• Prescribed diet: low potassium and phosphorus on top of other diet;
this complex diet might need the involvement of a dietician.
• ACE-inhibitor and possibly eplerenone dosage should be adjusted
and renal function closely monitored (by whom?)
• Heart failure might result in worsening kidney function and vice versa,
requiring a close collaboration between caregivers
• Various potential interactions between drugs (this patient requires
approximately 12 different drugs!) require specific attention
• Adherence of the patient might be poor given the number of medication
y years, LVEF left ventricular ejection fraction, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, ICD internal cardioverter defibrillator,
NSAID non-steroidal anti-inflammatory drug, GP general practitioner
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patients with even more co-morbidities and more drugs.
Management of such patients is challenging and not only
requires good communication between caregivers, pa-
tients and their relatives but also requires prospective
treatment trials addressing this important issue.
In summary, current care for patients with heart failure and
related co-morbidities is far from being optimal, which
leaves a large margin for improvement
From all these issues in diagnosis, treatment, chronic care,
interactions between stakeholders and available evidence for
heart failure patients with co-morbidities, major underlying
issues can be pointed out: firstly, there is lack of interaction,
sufficient communication and knowledge exchange between
patients and their caregivers as well as among caregiverswith different expertise. Secondly, care is largely unidirec-
tional from individual caregivers to patients, with virtually
absent personal responsibility by the patients. Thirdly, the
lack of clinical evidence for patients with multiple chronic
diseases heavily hampers the care of these patients. Fourthly,
ICT/tele-medicine plays so far an isolated, limited role and
is used in addition to other care instead of as substitution of
parts of care, and data exchange is not integrated in care
(Fig. 3). Unfortunately, there is currently no framework
available addressing these issues.
Innovative PPPM approach in management of chronic
diseases
Based on the considerations regarding current gaps in
personalised treatment of patients with heart failure and
multiple co-morbidities, several aspects of health care
Fig. 3 Current one-directional care in chronic diseases (green refers
to primary care, brown to specialist care)
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may result not only in better treatment of individual pa-
tients with chronic diseases resulting in better outcome
and quality of life, but also in better prediction of such
needs and in the prevention of both progression of dis-
ease(s) and development of additional chronic disorders.
– Collaboration, interaction and communication
between all persons involved in the care of chronic
diseases needs to be substantially improved. The
patient must be central in his/her management
system, as person-centred care in heart failure seems
to be promising [51]. All involved caregivers must
have access to the information about the patient.
Therefore, central ICT and easy data exchange are
important. The patient (and his/her representative if
required) provides rights to access the information.
– Patient involvement for the development of new ICT
platforms is crucial to define the requirements in view of
the fact that the typical patient with chronic diseases is
elderly with difficulties to understand and use standard
ICT equipment. In order to support acceptance and
later adoption of the new system, the innovation process
should include not only the perspective of the patient,
but also the needs of the other stakeholders in the care
of chronic diseases. Constant feedback during the
development process is important.
– Analysis and integration of multiple guidelines are
crucial. Therefore, multidisciplinary committees
should be formed to address this issue. Moreover,
multidisciplinary prospective cohorts with (long-
term) follow-up are needed.– Prediction of outcome should be improved by
addressing multiple chronic diseases and focusing on
short-term changes that may be able to predict
long-term outcome and respond to personalised
treatment. This may allow steering the individualised
care process more effectively and efficaciously.
– Prospective treatment trials addressing multiple
chronic diseases are required.
– Progress requires not only novel and innovative
technology but also an innovative and novel vision
of care and health.
Obviously, this list cannot be exhaustive in covering all
future needs. Also, various initiatives and projects are re-
quired to address all these issues as it is impossible to
address them all together. Moreover, it may take years
until significant progress is being made. However, very
little attempts are being made so far in this regard and a
paradigm shift is required in health care. Only then, the
imminent problems in health care can be tackled to pro-
vide good quality care at affordable costs for all.
Conclusions
Health care in Western countries requires a new innova-
tive approach to address chronic diseases such as heart
failure to provide sustainability of care and to limit the
excessive costs that may threaten the current system.
The increasing prevalence of chronic diseases together
with their enormous economic impact and the increas-
ing shortage of health care providers are amongst the
most critical threats. Attempts to solve these problems
have failed so far. Future limitations in financial re-
sources will result in a significant reduction in the qual-
ity of care. Thus, changing the approach to care of
chronic diseases is of utmost social importance. This
needs not only adoption and smarter use of modern
technology, but also new a vision on both care and
health.
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